➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Dow
Moodys
Harvard Business School
McKinsey

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for LY2606368


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for LY2606368?

LY2606368 is an investigational drug.

There have been 16 clinical trials for LY2606368. The most recent clinical trial was a Phase 1 trial, which was initiated on April 10th 2018.

The most common disease conditions in clinical trials are Neoplasms, Leukemia, Myeloid, Acute, and Neoplasm Metastasis. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and National Cancer Institute (NCI).

There are three US patents protecting this investigational drug and sixty-seven international patents.

Recent Clinical Trials for LY2606368
TitleSponsorPhase
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsEli Lilly and CompanyPhase 1
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsSt. Jude Children's Research HospitalPhase 1
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialEli Lilly and CompanyPhase 1

See all LY2606368 clinical trials

Clinical Trial Summary for LY2606368

Top disease conditions for LY2606368
Top clinical trial sponsors for LY2606368

See all LY2606368 clinical trials

US Patents for LY2606368

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LY2606368   Start Trial 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate Eli Lilly and Company (Indianapolis, IN)   Start Trial
LY2606368   Start Trial Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA)   Start Trial
LY2606368   Start Trial 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-- carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts Eli Lilly and Company (Indianapolis, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LY2606368

Drugname Country Document Number Estimated Expiration Related US Patent
LY2606368 Argentina 106772 2035-12-07   Start Trial
LY2606368 Australia 2016367041 2035-12-07   Start Trial
LY2606368 Brazil 112018008398 2035-12-07   Start Trial
LY2606368 Canada 3003914 2035-12-07   Start Trial
LY2606368 Chile 2018001432 2035-12-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Boehringer Ingelheim
Harvard Business School
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.